

Correction

CircZCCHC2 decreases pirarubicin sensitivity and promotes triple-negative breast cancer development via the miR-1200/TPR axis

Fan Zhang, Dexian Wei, Shishun Xie, Liqun Ren, Sennan Qiao, Liying Li, Jiahua Ji, and Zhimin Fan*

(iScience 27, 109057, 1–22; March 15, 2024)

In the original published version of this article, Figures 6E, 6F, S3E, and S3F are duplicates. Data from Figures 6E, 6F, S3E, and S3F were initially placed in the same figure and split during the revision process. During the revision process, an incorrect cell line was erroneously placed in Figures S3E and S3F. Thus, the corrected version of Figure S3 has been provided here, and the original article has been corrected online. The discussion and conclusions of this paper remain unchanged even after the corrections. The authors apologize for any inconvenience caused to the readers.

*Correspondence: fanzm@jlu.edu.cn
<https://doi.org/10.1016/j.isci.2024.109786>






Figure S3. MiR-1200 promotes malignant transformation in TNBC through TPR (original)




Figure S3. MiR-1200 promotes malignant transformation in TNBC through TPR (corrected)